乙-氨酸辅助的糖溶性重编程燃料TNBC进展:用XAV93939进行治疗阻塞
Sheikh Mohammad Umar1, Shruti Kahol2, Sandeep R Mathur2
1Department of Medical Oncology (Lab), Dr BRA IRCH, AIIMS, Ansari Nagar, New Delhi, India.
Technology in cancer research & treatment
|February 17, 2026
概括
在三阴性乳腺癌 (TNBCs) 中,β-catenin驱动有氧糖解和转移. 用XAV939抑制β-catenin抑制了TNBC的进展,并显示出治疗潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 甘油性表型促进癌细胞迁移和转移,特别是在三阴性乳腺癌 (TNBCs) 中.
- 了解推动TNBCs有氧糖解的分子途径对于识别进展驱动因素至关重要.
研究的目的:
- 研究β-catenin在TNBCs中调节有氧糖解中的作用.
- 在TNBC模型中评估β-catenin抑制剂XAV939的治疗潜力.
主要方法:
- 免疫组织化学 (IHC) 在98名TNBC患者中评估了β-catenin和糖解蛋白 (PFKP,LDHA,MCT1).
- 卡普兰-梅尔和考克斯回归分析了预后价值.
- 在体外研究中使用了XAV939与MTT,西部斑点,伤口愈合,入侵和殖民地形成试验.
主要成果:
- 在超过50%的TNBC中,β-catenin和糖溶性标记物过度表达.
- 结合表达与患者存活率降低相关.
- XAV939抑制了β-catenin,糖解蛋白和有氧糖解,损害了TNBC细胞的增殖,迁移,入侵和克隆性.
结论:
- β-catenin通过调节关键的糖溶性蛋白质,对TNBC进展和转移产生关键的控制有氧糖解.
- XAV939有效地抑制了糖溶性表型,表明它对TNBC治疗的治疗承诺.
相关概念视频
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
03:03mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K